Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibody discovery outfit Adimab LLC has added two big biotechs to its stable of partners and promises a shift in partnering strategy for 2012.
You may also be interested in...
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
Deals Of The Week’s Takeaway From PSA: Optimism With Aches
The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.
Deals Of The Week: Tellingly, Teva And Lonza Part Ways
Teva and Lonza agree to dissolve their four-year-old biosimilars joint venture, created at a time when the biosimilars opportunity seemed huge, if vague. In an otherwise slow deal-making week, next-generation antibody platform company Adimab forged two transforming deals with GSK and Biogen, while Kolltan and the Children’s Hospital of Philadelphia plunged into neuroblastoma.